Doris is 85 and suffers from moisture build up in her eye, what some call wet eye. She is on Medicare and gets treated with Eylea, a Regeneron product, every 4-5 weeks. Each treatment costing $6,200. That is more than $70,000 per year even though Doris never made more than $40,000 while working. Her total out of pocket cost is $10.29 per treatment.
Posts Tagged ‘Cashflow’
25-Jul 2017: Regeneron’s Eylea: Pulling Open the Curtain on Drug Costs
Posted in bill parish, Drug companies, Uncategorized, tagged 990, Avastin, Bayer, Bloomberg, Cashflow, DRI Capital, Drug companies, Drug costs, Drug Royalty III L.P. 1, Drugmakers, eylea, FDA, Foundations, GoodDays, Health insurance, Healthcare, Income Tax, Insurance, investments, irs, Medicaid, Medicare, OIC, Opthomologists, Oregon-PERS, Pablo Legorreta, Patient Access Network, Patient Cash Flows, public pensions, Regeneron, Royalty, Royalty Pharma, State of Oregon, tax exempt, Tax Inversions, Wet AMD on July 25, 2017|
